SPARCL1 and neoplasm: Of the 53 mRNA probes which robustly separated tumour from normal samples, 44 (BUB1, TPX2, CDC25C, ASPM, C1orf112, KIF23, CENPA, HJURP, CCNA2, TTK, CCNB2, C12orf48, BIRC5, RAD51AP1, RACGAP1, MELK, KIFC1, NCAPG, EXO1, KDM2A, EHMT2, DNA2, E2F3, C8orf30A, FAM64A, CORO1B, HEATR3, NCAPH, PSMB2, ERCC6L, KIF15, ESPL1, RANGAP1, KIF11, SCAMP5, NUSAP1, GINS1, ZWINT, ASF1A, an unannotated probe 217205_at, and two probes each for TOP2A and AURKA) were up-regulated and 9 (DNAH3, C6, ADH6, SERPINA6, GCLC, DNAI1, SPARCL1, and two probes for DNAH9) were down-regulated in tumour compared to normal.